Overall, our study suggests an increase in the CD34+ cell counts in AD patients compared to controls; however, these results must be interpreted with caution due to the substantial heterogeneity and the concerns regarding the risk of bias in the included studies. This evidence concerns the gene CD34 and Alzheimer disease.